Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Quiet Board

<< Previous

Bullboard Posts

Next >>

Comment by stockfyon Mar 15, 2021 11:56am

105 Views

Post# 32798866

RE:RE:RE:RE:RE:RE:Quiet Board

Stocker46, I know it hurts. It hurts a lot. I'm sorry my friend. I'm sorry that you bought CPH above C$10 a few years ago and you sold it well below C$10, according to your own previous statements. So I'm sorry that you recorded such a big loss. As a result, you are now a desperate hater who regularly twists the truth, makes misleading comments and posts unfounded speculation trying to make the weak hands sell CPH at an insanely low valuation. This is how you hope to recover part of your big losses. Your plan makes sense to me.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals